Immunomodulator SCV-07 for Allergic Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic diseases, such as asthma, are inefficient and often have significant side effects due to non-selective immune system activation and high toxicity, with existing therapies failing to effectively reduce symptoms and hyperreactivity.
Innovation Solution
The use of immunomodulator compounds, specifically γ-D-glutamyl-L-tryptophan (SCV-07), which modulates the immune response by shifting the balance of T-helper cells towards Type 1, reducing eosinophilia and bronchial hyperreactivity, administered through various routes to achieve targeted therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (anti-inflammatories, antihistamines, corticosteroids) are used to treat allergic diseases, then symptom relief is provided, but treatment efficiency is low and side effects are significant
Solution Approach 1:
The patent changes the fundamental parameter of immune regulation by introducing a compound that shifts the Th1/Th2 balance, rather than simply suppressing symptoms. This parameter change enables effective treatment with reduced side effects by addressing the root cause of allergic disease through selective immune modulation.
Solution Approach 2:
The patent uses an intermediary substance (the immunomodulator compound) that mediates between the immune system and allergic response. This compound acts as a selective regulator that promotes Th1 cytokine production without causing the broad suppression and side effects of conventional treatments.
2Quantity of substance
If IFN-γ is administered to shift T-helper balance towards Type 1, then Th1 response is enhanced, but bronchial hyperreactivity increases and treatment reliability is insufficient
Solution Approach 1:
The patent applies local quality by creating a compound with specific molecular structure (γ-glutamyl dipeptide) that selectively modulates immune response. This localized molecular design enables the compound to enhance Th1 response without causing the adverse effects of non-selective IFN-γ administration, achieving consistent and reliable treatment.
Solution Approach 2:
The patent uses a composite approach by combining γ-glutamyl dipeptide structure with specific amino acid sequences to create an immunomodulator with balanced properties. This composite molecular structure enables simultaneous enhancement of Th1 response and reduction of side effects, improving treatment reliability.
3Quantity of substance
If recombinant interleukin-12 is administered to reduce eosinophilia, then eosinophil levels decrease, but bronchial hyperreactivity and symptoms persist with high toxicity
Solution Approach 1:
The patent employs a short-lived, naturally metabolizable dipeptide structure that provides transient but effective immune modulation. This approach reduces cumulative toxicity compared to persistent recombinant cytokines, while still achieving the desired reduction in eosinophilia and improvement in symptoms.
4Power
If IL-18 is administered to activate T-helper clones, then immune response is enhanced, but allergic manifestations increase due to polyclonal activation
Solution Approach 1:
The patent inverts the approach by using a compound that selectively promotes Th1 differentiation rather than broad polyclonal activation. This inverted strategy of targeted differentiation, rather than general activation, enhances immune power while preventing the exacerbation of allergic manifestations.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method of treatment for treating, preventing, inhibiting or reducing allergic disease or its effects in a subject, comprises administering to the subject an effective amount of an immunomodulator compound, which comppses an aromatic or heterocyclic amino acid residue or a depvative thereof Preferably, the immunomodulatory compound is a dipeptide which comprises a D- or L-tryptophan residue.